The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Updates from a Phase I study evaluating dendritic cell therapy, cryosurgery & pembrolizumab in NHL
In this video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some updates from a Phase I study evaluating dendritic cell therapy, cryosurgery, and pembrolizumab for the treatment of non-Hodgkin lymphoma (NHL). Dr Lin first explains the biology behind dendritic cell therapy, and then goes on to discuss some of the results obtained. To conclude, Dr Lin highlights the potential role of this approach in deepening responses in the post-CAR-T setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
